New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Amgen posted earnings that were better than expected last month. Because Amgen stock has heavy institutional ownership, ...
Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024 ...
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback